NCT06734572View on ClinicalTrials.gov

18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

October 1, 2025

Study Completion Date

December 31, 2025

Conditions
Malignant Neoplasm
Interventions
DRUG

18F-FAPIBiotin

The dose will be 148-296 MBq given intravenously.

Trial Locations (1)

350005

RECRUITING

Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER